Braslyn Ltd. is 10% Owner at Mirati Therapeutics, Inc. (MRTX). They have made 15 open-market trades across 2 companies since 2016, most recently 2021-03-10.
CIK 0001642355
11 open-market purchases totalling $21.9M since 2016, against 4 sales. Across 11 scored buys the stock is down 32.5% at ninety days, and 35.7 points behind the S&P over the same stretch.
11 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 36% | 73% | 9% |
| Avg Move | -1.1% | -3.2% | -32.5% |
| Alpha | -1.5% | -6.1% | -35.7% |
| Scored | 11 | 11 | 11 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MRTX | SELL | 2021-03-09 | 2021-03-10 | $197.65 | $4.8M | -4.0% | -11.4% | -11.3% |
| INSG | SELL | 2020-12-14 | 2020-12-16 | $15.44 | $73.6M | +6.1% | -3.9% | -27.0% |
| MRTX | SELL | 2020-06-12 | 2020-06-16 | $97.00 | $58.2M | +6.4% | +14.5% | +36.6% |
| MRTX | SELL | 2019-03-01 | 2019-03-05 | $69.00 | $19.0M | +5.8% | -0.1% | +23.6% |
| MRTX | BUY | 2017-11-16 | 2017-11-20 | $13.00 | $5.2M | -9.9% | -9.4% | +49.5% |
| MRTX | BUY | 2017-01-26 | 2017-01-30 | $5.45 | $525K | +14.9% | +13.9% | -13.9% |
| MRTX | BUY | 2017-01-23 | 2017-01-25 | $5.33 | $663K | -2.8% | +3.7% | -14.8% |
| MRTX | BUY | 2017-01-18 | 2017-01-20 | $5.46 | $579K | -3.8% | +16.0% | -13.2% |
| MRTX | BUY | 2017-01-12 | 2017-01-17 | $5.49 | $946K | -2.7% | +7.1% | -25.9% |
| MRTX | BUY | 2017-01-06 | 2017-01-10 | $5.60 | $3.3M | -4.5% | +4.5% | -12.6% |
| MRTX | BUY | 2016-06-06 | 2016-06-08 | $9.96 | $7.5M | -28.7% | -40.3% | -45.1% |
| MRTX | BUY | 2016-05-05 | 2016-05-09 | $18.25 | $2.3M | -8.0% | -45.8% | -66.9% |
| MRTX | BUY | 2016-03-29 | 2016-03-31 | $19.09 | $65K | +6.3% | +1.3% | -74.2% |
| MRTX | BUY | 2016-03-24 | 2016-03-28 | $19.36 | $801K | +18.1% | +8.8% | -71.7% |
| MRTX | BUY | 2016-03-18 | 2016-03-22 | $19.34 | $23K | +9.2% | +5.2% | -68.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.